1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
137.32 USD   +4.29%
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts BeiGene's Price Target to $360 from $407, Keeps Overweight Rating

01/18/2022 | 12:20pm EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 438 M - -
Net income 2022 -1 382 M - -
Net cash 2022 2 802 M - -
P/E ratio 2022 -9,58x
Yield 2022 -
Capitalization 14 168 M 14 168 M -
EV / Sales 2022 7,91x
EV / Sales 2023 5,92x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 137,32 $
Average target price 307,42 $
Spread / Average Target 124%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-49.32%14 168
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612